New tool aims to simplify tough choices for lung cancer patients

NCT ID NCT05191485

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to create a decision aid for people with lung adenocarcinoma who need to decide whether to have molecular testing after surgery. Researchers will interview patients, family members, and doctors to understand what information is needed. The final tool will be tested with 190 participants to see if it helps patients and doctors make shared decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could provide a tool to help patients and doctors make more informed decisions about molecular testing after lung cancer surgery.

What could go wrong

This is an early-stage study focused on developing and testing a decision aid, not on treatment outcomes. The tool may not change patient decisions or improve health results.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SURGERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung lung adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sichuan Cancer Hospital & Institute

    RECRUITING

    Chengdu, Sichuan, 610041, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact